New pill plus chemo shows early promise in tough pancreatic cancer
NCT ID NCT05586516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an experimental oral drug called IOA-289 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in 16 people with metastatic pancreatic cancer. The main goal was to check safety and find the right dose. Researchers also looked at how the drug behaves in the body and any signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IOA-289 (an experimental oral drug) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If it works, this could point toward a new treatment option for metastatic pancreatic cancer by adding an oral drug to standard chemotherapy.
What could go wrong
This is a very early, small trial (16 people) focused on safety and dosing, not yet on effectiveness. The drug may not work or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Center
Glasgow, G12 0YN, United Kingdom
-
Medical Oncology and Immunotherapy Unit, University Hospital of Siena
Siena, 53100, Italy
-
UO Oncologia of Azienda Ospedaliera Universitaria Integrata di Verona
Verona, Verona, 37126, Italy